Please login to the form below

Not currently logged in
Email:
Password:

baloxavir marboxil

This page shows the latest baloxavir marboxil news and features for those working in and with pharma, biotech and healthcare.

Roche’s new flu pill Xofluza approved in US

Roche’s new flu pill Xofluza approved in US

The FDA has approved Roche’s new flu treatment Xofluza (baloxavir marboxil), the first new antiviral drug in nearly 20 years.

Latest news

  • Encouraging data for Roche flu drug ahead of FDA decision Encouraging data for Roche flu drug ahead of FDA decision

    complications. Baloxavir marboxil is a single-dose, investigational oral medicine, and has just achieved its primary endpoint in the CAPSTONE-2 trial comparing it with placebo and Tamiflu. ... If approved, baloxavir marboxil will be the first single-dose

  • Roche’s Tamiflu successor hits the mark in complicated flu Roche’s Tamiflu successor hits the mark in complicated flu

    Baloxavir marboxil met its primary objective and cut flu-related complications. Roche has reported a second pivotal data on a novel influenza drug – baloxavir marboxil – that it says is the first ... With baloxavir marboxil Roche now looks like it

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics